Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaDasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLThe role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Management of chronic myeloid leukemia in blast crisis.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.Dasatinib monotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with pulmonary infection in induction remission: A case report and review of the literature
P2860
Q26768158-6B52DBB0-9C53-4EDE-BE00-69D17CF92699Q27025242-82C7D822-EB85-4CBD-8491-0685190FA67CQ37376595-8AB579B4-C2A0-4D98-8F7B-EABD74A5C210Q38375425-5A52218E-23F6-4454-9F6D-F09FD3641637Q38392682-67C5F30E-FFD4-4539-A5A0-15E806F4B9B2Q38469746-79A4EACA-9847-425D-89C9-38A0CAEB0741Q38521775-58123721-0338-4E2F-B91A-9DE6C91E2743Q38734309-7BE495E1-9BFE-49C5-9B3F-AD5A90DA7945Q39022777-85A7AD31-065E-4345-A829-545F861DBC51Q40533806-B1AE3859-52CF-4A17-9E75-EA7756B017A7Q40721566-D55FA23F-0B06-46C5-9E30-9A90B174438EQ47710825-C1F66663-500A-443A-BF78-EFAD656BDA49Q48119645-822108C4-88AE-4FDA-8138-00CAB6A4DBD7Q52681024-CDA35E08-CE18-400B-B4E1-EDC11E979B34Q58703906-9CE2229E-C7DB-4542-8D47-D7ADB59F4F60
P2860
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Phase II trial of hyper CVAD a ...... hase chronic myeloid leukemia.
@en
type
label
Phase II trial of hyper CVAD a ...... hase chronic myeloid leukemia.
@en
prefLabel
Phase II trial of hyper CVAD a ...... hase chronic myeloid leukemia.
@en
P2093
P2860
P50
P921
P356
P1476
Phase II trial of hyper CVAD a ...... hase chronic myeloid leukemia.
@en
P2093
Deborah Thomas
Jan Burger
Jeffrey Jorgensen
Ohad Benjamini
Partow Kebriaei
Rajyalakshmi Luthra
Rebecca Garris
Richard Champlin
Theresa Liu Dumlao
P2860
P304
P356
10.1002/AJH.23624
P50
P577
2014-03-01T00:00:00Z